MRD-guided treatment with ibrutinib and venetoclax for CLL in the FLAIR trial

Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, comments on the FLAIR study (ISRCTN01844152), investigating a measurable residual disease (MRD)-driven approach to the administration of ibrutinib and venetoclax for patients with chronic lymphocytic leukemia (CLL). This study shows that the majority of patients maintained MRD negativity, with few relapses, suggesting that MRD-driven therapy can induce good remissions in most patients with CLL when combining ibrutinib and venetoclax. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.